New cancer pill shows promise in early trial
NCT ID NCT05025358
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new oral drug called LP-118 in 68 people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. LP-118 works by blocking two proteins that help cancer cells survive. The main goals were to find a safe dose and check for side effects, while also looking for signs that the drug might shrink tumors. Results will help decide whether to test LP-118 in larger trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LP-118 (a BCL-2/BCL-XL inhibitor)
- What this could lead to
- If successful, this could point toward a new treatment option for advanced solid tumors and lymphomas that have not responded to other therapies.
- What could go wrong
- This is an early Phase 1 trial with only 68 participants, focused on safety and dosing. It is too small and early to know if LP-118 will work or be safe for wider use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310006, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
-
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, 510632, China
-
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a new infusion drug tame advanced solid tumors?
- Can a radioactive injection target bone tumors? a Dose-Finding trial aims to find out